Shortly after ponsegromab, visugromab is to start phase 2/3.
ApexOnco Front Page
Recent articles
J&J, Astra, Pfizer and others move yet more ADCs into human studies.
The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.
Data on PMV’s p53 reactivator prompt a 26% selloff before their presentation, and 48% afterwards.
Tempest Therapeutics confirms an earlier success with its lead project, and this time investors respond.
The once-hyped group’s most advanced hope is an allogeneic CD19 Car-T, where competition is fierce.
Ideaya and GSK join Novartis and Roche in the Werner helicase inhibitor race.
The acquisition brings closure for Mirati at last, though some investors will feel disappointed.